Cetuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Cetuximab
- Pharmacist Assessment Report
- Cetuximab: EGFR-targeted monoclonal antibody → bronchial adenomas/carcinoids childhood
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cetuximab: EGFR-targeted monoclonal antibody → bronchial adenomas/carcinoids childhood
One-Sentence Summary
Cetuximab is an anti-EGFR monoclonal antibody marketed in Australia as Erbitux. The TxGNN model predicts it may be relevant to bronchial adenomas/carcinoids childhood, but no clinical trials and no publications were found for this disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | bronchial adenomas/carcinoids childhood |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Cetuximab is known to bind the epidermal growth factor receptor (EGFR), and the pharmacology data lists EGFR as its target.
The data compiled for this report does not support a link between EGFR blockade and childhood bronchial carcinoids. No trial or publication addresses this disease, and the mechanistic rationale is therefore unconfirmed. The prediction should be treated as a hypothesis for further investigation, not as a supported use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10262D | Erbitux | Solution for I.V. infusion 100 mg in 20 mL | Not recorded in the local data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the Product Information (PI) warnings and precautions |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |
Safety Considerations
- Drug Interactions: 20 interaction records were compiled. Two are rated Major: aminolevulinic acid and thalidomide. Most others are rated Moderate, including proton pump inhibitors (rabeprazole, omeprazole, dexlansoprazole, esomeprazole, lansoprazole, pantoprazole), platinum agents (cisplatin, carboplatin, oxaliplatin), fluorouracil, capecitabine, idelalisib, methoxsalen, verteporfin, omacetaxine mepesuccinate and topical photosensitising agents.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score (0.9995) but no trials or publications directly studying childhood bronchial adenomas/carcinoids, so the evidence level is L5.
To proceed, the following is needed:
- Published or registered studies directly addressing EGFR targeting in childhood bronchial carcinoids
- Mechanism of action data to support a biological rationale
- The TGA Product Information, to review warnings and contraindications
- A paediatric-specific safety and dosing assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.